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Abstract
Introduction Refractory septic shock has dismal prognosis
despite aggressive therapy. The purpose of the present study is
to report the effects of terlipressin (TP) as a rescue treatment in
children with catecholamine refractory hypotensive septic
shock.
Methods We prospectively registered the children with severe
septic shock and hypotension resistant to standard intensive
care, including a high dose of catecholamines, who received
compassionate therapy with TP in nine pediatric intensive care
units in Spain, over a 12-month period. The TP dose was 0.02
mg/kg every four hours.
Results Sixteen children (age range, 1 month–13 years) were
included. The cause of sepsis was meningococcal in eight
cases, Staphylococcus aureus in two cases, and unknown in six
cases. At inclusion the median (range) Pediatric Logistic Organ
Dysfunction score was 23.5 (12–52) and the median (range)
Pediatric Risk of Mortality score was 24.5 (16–43). All children
had been treated with a combination of at least two
catecholamines at high dose rates. TP treatment induced a rapid
and sustained improvement in the mean arterial blood pressure
that allowed reduction of the catecholamine infusion rate after
one hour in 14 out of 16 patients. The mean (range) arterial
blood pressure 30 minutes after TP administration increased
from 50.5 (37–93) to 77 (42–100) mmHg (P  < 0.05). The
noradrenaline infusion rate 24 hours after TP treatment
decreased from 2 (1–4) to 1 (0–2.5) µg/kg/min (P < 0.05).
Seven patients survived to the sepsis episode. The causes of
death were refractory shock in three cases, withdrawal of
therapy in two cases, refractory arrhythmia in three cases, and
multiorgan failure in one case. Four of the survivors had
sequelae: major amputations (lower limbs and hands) in one
case, minor amputations (finger) in two cases, and minor
neurological deficit in one case.
Conclusion TP is an effective vasopressor agent that could be
an alternative or complementary therapy in children with
refractory vasodilatory septic shock. The addition of TP to high
doses of catecholamines, however, can induce excessive
vasoconstriction. Additional studies are needed to define the
safety profile and the clinical effectiveness of TP in children with
septic shock.
Introduction
Septic shock is a severe clinical condition with a complex
pathophysiology and poor prognosis despite intensive therapy
[1,2]. In sepsis, a cascade of macrocirculatory and microcircu-
latory alterations may induce an inability to maintain vasocon-
striction, and can lead to severe hypotension [3]. When
hypotension becomes refractory to current intensive treat-
ments, the prognosis of septic shock is very poor [4,5].
AVP = vasopressin; MAP = mean arterial pressure; PICU = pediatric intensive care unit; TP = terlipressin.Critical Care    Vol 10 No 1    Rodríguez-Núñez et al.
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Table 1
Clinical characteristics of patients before terlipressin treatment
Patient Sex Age 
(months)
Weight 
(kg)
Underlying disease Cause of sepsis Pediatric 
Logistic Organ 
Dysfunction 
score
Pediatric Risk 
of Mortality 
score
Prior ischemia Other data
1 Male 15 12 No Meningococcus 34 38 Limbs, 
cutaneous
2 Female 156 47 No Meningococcus 22 17 No Coagulopathy
3 Female 36 15 VATER association 
(vertebral defects, 
anorectal atresia, 
tracheoesophageal 
fistula, renal 
anomalies)
Unknown 
(nosocomial)
32 21 Intestinal ARDS, 
coagulopathy
4 Male 144 35 Cranial trauma Unknown 
(nosocomial)
30 32 No ARF, hyperkalemia, 
refractory 
intracranial 
hypertension
5 Male 36 16 No Meningococcus 43 25 Four limbs 
(severe), 
cutaneous, 
intestinal
ARF, rabdomyolisis, 
severe metabolic 
acidosis
6 Male 15 12 No Meningococcus 24 35 Limbs, 
cutaneous
No
7 Female 7 7 No Meningococcus 23 19 Limbs, 
cutaneous
ARF, coagulopathy
8 Male 46 20 No Unknown 12 26 No Severe 
rabdomyolisis
9 Male 56 32 No Meningococcus 23 30 No Prior cardiac arrest
10 Female 2 4 Congenital metabolic 
disease?
Unknown 22 18 No ARF, metabolic 
acidosis
11 Male 156 43 Cerebral palsy Unknown 
(nosocomial)
31 19 No No
12 Male 46 18 No Meningococcus 23 24 No Coagulopathy
13 Male 115 39 No Unknown 
(pneumococcus?)
20 27 Limbs, 
cutaneous
Prior cardiac arrest, 
ARDS, ARF
14 Female 72 25 Rabdomyosarcoma Staphylococcus 
aureus
52 43 No No
15 Male 24 13 No Meningococcus 33 22 Limbs, 
cutaneous
ARF, coagulopathy
16 Male 1 4 Propionic acidemia Staphylococcus 
aureus
21 24 No Severe metabolic 
acidosis
ARF, acute renal failure; ARDS, acute respiratory distress syndrome.
Prompted by the desperate situation of patients who fail to
respond to aggressive therapy with fluid expansion, vasopres-
sors, inotropes, and other therapies, alternative or complemen-
tary vasoconstrictors have been used [3]. Vasopressin (AVP)
has potent vasoconstrictive effects mediated via V1 receptors
and has been shown effective in catecholamine-resistant
hypotension due to septic shock [5-10].
Terlipressin (TP) is a synthetic analog of AVP with a similar
pharmacodynamic profile, but with a significantly longer half-
life, that has showed promising effects in some case reports
of adult patients [11-16] and of children with refractory
vasodilatory septic shock [4,17-19]. On the other hand, con-
cerns have been raised about possible adverse effects of
these alternative pressor agents [20-22]. New clinical evi-
dence is therefore needed to define the role of both AVP and
TP in vasodilatory septic shock [4,15,22,23].
In the present article, we report the results of the use of TP as
a last-resource compassionate therapy in critically ill children
with catecholamine-resistant hypotension due to septic shock.
Patients and methods
A prospective, multicenter, observational study was carried
out in nine pediatric intensive care units (PICUs) in Spain, dur-
ing a 12-month period (July 2004–June 2005). Indication of
treatment was made by the responsible physician, and admin-
istrative authorization was obtained after fulfillment of the strictAvailable online http://ccforum.com/content/10/1/R20
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legal and ethical conditions for compassionate use of drugs
required in our country [24]. Briefly, compassionate therapy
permits the use of a non-licensed drug or a drug licensed for
other indications, outside a clinical trial, in desperate clinical
situations where the responsible doctor considers that no
other therapeutic alternatives exist and after a specific
informed consent process has been carried out.
Inclusion criteria included septic shock with refractory hypo-
tension, defined by an inability to maintain a mean arterial pres-
sure (MAP) above the third percentile for age despite fluid
resuscitation and 'high catecholamine doses' (at least 1 µg/
kg/min noradrenaline or adrenaline, associated with variable
doses of dopamine and/or dobutamine), or evidence of
adverse effects of catecholamines (ischemia, arrhythmias).
Patients aged from one month to 15 years were eligible. Chil-
dren with cardiac diseases were excluded.
Due to the lack of specific treatment recommendations, we
decided to maintain the TP dosage used in previous pediatric
cases [17]: 0.02 mg/kg every four hours by intravenous bolus
for a maximum of 72 hours. The main objective of TP treatment
was to improve survival of the episode; specific objectives
were to achieve and maintain MAP values within the normal
range for age and, when possible, to lessen the noradrenaline
and adrenaline infusion rates.
Statistical analysis
Values are presented as the median (range). Nonparametric
tests were used and intragroup comparisons were performed
using the Wilcoxon test. P < 0.05 was considered statistically
significant. The inotropic equivalent was calculated by means
of a previously described formula [25].
Results
Sixteen children, with ages ranging from one month to 13
years, were included in the study. Patient characteristics are
presented in Table 1. Sepsis was caused by Neisseria menin-
gitides in eight cases and by Staphylococcus aureus in two
cases; no bacteria were isolated in the remaining six children
(sepsis was of nosocomial origin in three cases). At PICU
admission, the median (range) Pediatric Logistic Organ Dys-
function score was 23.5 (12–52) and the median (range)
Pediatric Risk of Mortality score was 24.5 (16–43). Seven
patients already had signs of ischemia at the time TP treatment
was considered (Table 1). Six patients had acute renal failure,
four patients had coagulopathy, three patients had severe aci-
dosis, two patients had rhabdomyolysis, two patients had
acute respiratory distress syndrome, and one patient had
refractory intracranial hypertension. Two children had been
resuscitated from cardiac arrest (Table 1).
Prior to the start of TP treatment, 15 patients were being
mechanically ventilated and ten patients were being treated
with continuous renal replacement therapy. Corticosteroids
were administered to eight children, and other treatments
(antithrombin III, treatment of intracranial hypertension, plas-
mapheresis, fresh frozen plasma and activated C protein) were
each used in one case, respectively. All patients received a
combination of at least two catecholamines at high doses. The
median (range) rates were 21.5 (10–52) µg/kg/min for
dopamine (16 patients), 22.5 (5–40) µg/kg/min for dob-
utamine (12 patients), 2 (1–4) µg/kg/min for noradrenaline (14
patients), and 1.25 (0.4–4) µg/kg/min for adrenaline (12
patients). Three children also received milrinone, and another
child also received digoxine.
TP was started 24 (4–168) hours after admission and was
maintained for 24 (3–102) hours (Table 2). The hemodynamic
variables and catecholamine infusion rates after TP therapy
are summarized in Table 3.
The MAP significantly increased in all patients after TP admin-
istration, from 50.5 (37–93) mmHg pre TP administration, to
77 (42–100) mmHg 30 minutes after TP administration, and
to 69.5 (41–104) mmHg 1 hour after TP administration (P <
0.05). The heart rate did not change significantly (Table 3).
Treatment with TP permitted a significant reduction in the
noradrenaline infusion rate, from 2 (1–4) µg/kg/min pre TP
administration, to 1 (0–2.6) µg/kg/min 12 hours after TP
administration, and to 1 (0–2.5) µg/kg/min 24 hours later (P <
0.05) (Table 3).
Seven patients showed signs of ischemia prior to TP adminis-
tration; ischemia persisted or increased with TP treatment in
three cases, and improved in four cases (Figure 1). The other
nine patients had no signs of ischemia before TP therapy was
started. In this subset of nine patients, five developed ischemia
possibly related to TP treatment (Figure 1), one of which
showed severe limb and intestinal ischemia.
The responsible physicians considered that TP treatment
could be also related to other adverse effects: oliguria in two
cases, rhabdomyolysis in two cases, hyperkalemia in one
case, and hyperbilirrubinemia in another child (Table 2).
Seven patients survived the septic shock episode and nine
children died. Causes of death were refractory shock in three
cases, refractory arrhythmia in three cases, withdrawal of ther-
apy in two cases, and multiorgan failure in one case (Table 2).
In an adolescent with severe cranial trauma and refractory
intracranial hypertension, who developed a nosocomial sepsis
with severe hypotension and acute renal failure, TP administra-
tion produced severe cutaneous and limb ischemia that was
considered by the attending physician a direct factor contrib-
uting to death. One infant survived the shock episode but died
two weeks later, due to intractable propionic acidemia. In our
patients, the Pediatric Risk of Mortality score or the PediatricCritical Care    Vol 10 No 1    Rodríguez-Núñez et al.
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Table 2
Terlipressin (TP) treatment and outcome
Patient Time from PICU 
admission to TP 
therapy (hours)
Time of 
maintenance of TP 
therapy (hours)
Adverse effectsa PICU length of 
stay (days)
Survival of 
episode
Cause of 
death
Sequela
1 40 48 No 49 Yes Minor amputation 
(one right hand 
finger)
2 4 32 Ischemia (limited to toes) 7 Yes No
3 12 65 No 51 No Refractory 
shock
4 6 3 Severe limbs and 
cutaneous ischemia, 
hyperkalemia
6 No Ventricular 
fibrillation
52 4 2 4 L i m b s  a n d  c u t a n e o u s  
ischemia
22 Yes Major amputation: 
lower limbs 
(below knees) 
and both hands
6 72 102 No 49 Yes Minor amputation 
(one hand finger)
7 26 8 Severe limbs ischemia, 
cutaneous ischemia, 
hyperbilirubinemia
14 No Withdraw of 
therapy
8 48 20 Rabdomyolisis? 22 Yes No
9 4 5 Oliguria 9 Yes Partial anopsy, 
dismetry
10 32 96 Cutaneous and intestinal 
ischemia
6N o W i t h d r a w  o f  
therapy
11 168 52 Limb and cutaneous 
ischemia, oliguria
8 No Multiorgan 
failure
12 14 7 No 1 No Arrhythmia
13 60 8 No 3 No Ventricular 
fibrillation
14 20 20 No 1 No Refractory 
shock
15 5 18 Limbs ischemia, 
rabdomyolisis
2 No Refractory 
shock
16 48 72 Limbs and cutaneous 
ischemia
14 Yes
PICU, pediatric intensive care unit. aBased in the opinion of the responsible physician
Logistic Organ Dysfunction score, age, sex, the time elapsed
until the start of TP administration, the catecholamine infusion
rate, the MAP, treatments with steroids, or the length of stay in
the PICU were not associated with mortality. Four of the survi-
vors developed sequelae. One patient suffered a major limb
amputation, including both lower limbs (below knees) and
both hands. Two children suffered the amputation of one fin-
ger, and another patient developed dysmetria and partial
anopsy. The length of the PICU stay was 8 (1–51) days (Table
2).
Discussion
Septic shock is a very complex condition, characterized by cir-
culatory failure. Its treatment has been based, in addition to
antibiotic therapy, on aggressive volume resuscitation and car-
diocirculatory support by means of the vasopressor and ino-
tropic effects of catecholamines [1-3,15,26,27]. Despite this
approach and intensive care and monitoring, septic shock
mortality and morbidity remain very high. New therapies are
therefore urgently needed [26,27].
AVP plasma concentrations are very high in cardiogenic or
hypovolemic shock [1,28]. In septic shock, however, a bipha-
sic response has been recognized, with high levels in the early
phase and inappropriately low AVP levels in established septic
shock [1,28,29]. This evidence and the potent vasopressor
effects of AVP prompted its use in vasodilatory septic shock.
AVP has been effective in restoring the MAP and vascular toneAvailable online http://ccforum.com/content/10/1/R20
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in adult patients [5-9,26] as well as in some pediatric case
series [10,30]. AVP has been also beneficial in the treatment
of excessive vasodilation associated with cardiopulmonary
bypass [31] and in postcardiotomy shock resistant to catecho-
lamine therapy [32-34].
TP is a long-acting synthetic analog of AVP that has also dem-
onstrated significant vasopressor effects in animal models
[35,36], in adult patients with norepinephrine-resistant septic
shock [11,13,14,16], and in a few pediatric cases with
vasodilatory shock [4,17-19]. A recently published trial com-
paring the short-time effects (only six hours) of noradrenaline
and TP treatment in adult patients with hyperdynamic septic
shock indicates that both drugs are effective in raising the
MAP and improving renal function [16].
To our knowledge, results of randomized clinical trials to
ascertain the effects of TP treatment, alone or in combination
with noradrenaline or other catecholamines, in pediatric
vasodilatory septic shock are lacking. The few case reports
available [4,17-19], however, suggest that TP has a possible
role in intractable septic shock, an issue that should be
explored.
We had previously reported the use of TP in four children with
septic shock resistant to high doses of noradrenaline, com-
bined with other catecholamines. In these patients TP therapy
induced a rapid and sustained improvement in MAP, which
allowed the lessening or even withdrawal of noradrenaline
infusion, without related adverse effects. Two patients sur-
vived [17].
Matok and colleagues recently reported their retrospective
experience with TP therapy in 14 children who suffered 16
septic shock episodes [4]. They observed significant improve-
ments in respiratory and hemodynamic indices shortly after TP
treatment. Adrenaline infusion was decreased or stopped in
eight patients. Six patients survived. No reference to adverse
effects was reported in this group of patients. Although all of
the children were considered to be in an extreme state of sep-
tic shock, eight patients had undergone correction of congen-
ital heart disease so a component of cardiogenic shock cannot
be ruled out, and this fact could interfere with the interpreta-
tion of results.
The present study is the first prospective and observational
study to report the clinical effects of TP administered as com-
Table 3
Evolution of hemodynamic variables and catecholamine infusion rates after terlipressin therapy
Before 
terlipressin 
therapy
Time after terlipressin therapy
30 min 60 min 4 hours 12 hours 24 hours 48 hours
Systolic blood 
pressure 
(mmHg)
77 (50–140) 108 (61–154)* 102.5 (61–137)* 99 (65–147) 91 (70–120) 107 (55–118) 105 (65–130)
Mean blood 
pressure 
(mmHg)
50.5 (37–93) 77 (42–100)** 69.5 (41–104)* 74 (40–95) 62 (40–90) 68 (35–90) 73 (40–103)
Diastolic blood 
pressure 
(mmHg)
38 (25–70) 57 (32–72)* 55.5 (31–90)* 48 (25–86) 50 (20–80) 48 (26–77) 53 (30–90)
Heart rate (beats/
min)
155 (80–205) 149 (114–186) 148 (85–190) 148 (110–190) 146 (114–185) 142 (102–170) 148 (101–170)
Central venous 
pressure 
(mmHg)
14 (4–23) 13 (3–23) 12.5 (3–17) 13 (3–27) 12 (4–24) 12 (5–18) 13.6 (5–22)
Catecholamines 
(µg/kg/min)
Noradrenaline 2 (1–4) 1 (0–3) 1.15 (0–3) 1.4 (0–2) 1 (0–2.6)* 1 (0–2.5)** 0.1 (0–1)**
Adrenaline 1.2 (0.4–4) 1 (0.5–6) 1 (0.3–4) 0.7 (0.2–3) 0.6 (0.1–2) 1 (0.2–2) 0.5 (0–2.5)
Dopamine 21.5 (10–52) 16.3 (3–40) 17.5 (0–52) 10 (0–40) 15.8 (0–40) 20 (3–40) 11.6 (0–45)
Dobutamine 22.5 (5–40) 20 (0–40) 20 (0–40) 20 (0–40) 20 (0–40) 20 (0–40) 22.5 (10–30)
Inotropic 
equivalenta
176 (141–552) 153.5 (67–460) 128.5 (57–340) 117.5 (20–340)* 82 (0–371)**
aInotropic equivalent: (noradrenaline × 100) + (adrenaline × 100) + dopamine + dobutamine + (milrinone × 15) [25].
* P < 0.05 versus baseline. ** P < 0.01 versus baseline.Critical Care    Vol 10 No 1    Rodríguez-Núñez et al.
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passionate therapy in children with refractory hypotension due
to septic shock. The patients were followed up until death or
PICU discharge. To avoid bias, we have excluded patients
with cardiac diseases. One-half of the patients had meningo-
coccal purpura fulminans. Despite these differences in the
patient characteristics analyzed, our results are comparable
with those of Matok and colleagues [4]. We have also
observed a significant increase in the MAP that permitted
decreasing the noradrenaline infusion rate without changes in
the heart rate (Table 3).
Noradrenaline and adrenaline, particularly at high doses, have
potent vasoconstrictive effects that can lead to irreversible tis-
sue ischemia [2,26,27]. Similar concerns arise when AVP and
TP are considered for reversing severe vasodilation in septic
shock [15,21,23]. When TP is used as a last-resource com-
passionate therapy, as in the present study, it is added to the
previous treatment, which in this case included combinations
of catecholamines in high doses. Such a synergy of effects
with an increase of previous tissue perfusion insufficiency or
its development could therefore be anticipated. In our series,
seven patients had signs of ischemia before TP administration;
interestingly, while ischemia persisted in three of them, it
improved in four children (Figure 1). On the other hand, five out
of nine patients without signs of ischemia developed skin and/
or limb ischemia after adding TP to the catecholamine dose
(Figure 1).
This heterogeneous response is intriguing. We can speculate
that improvement of tissue perfusion improvement could be an
indirect effect of restoring the MAP and that the development
or worsening of ischemia could result from the addition of
vasoconstrictive effects of catecholamines and TP or from a
direct effect of TP administration. It also appears from our
results that TP requirements may have great variability derived
from multiple patient characteristics, and the dosage should
be titrated according to clinical consequences (balance
between positive and adverse effects). One potential strategy
in this sense could be to administer a loading dose of TP fol-
lowed by a goal-directed variable intravenous infusion rate
[37].
Another point to be elucidated is the most adequate bolus
dose of TP. Due to the lack of specific dosage recommenda-
tions, we decided to use the same dosage as that utilized in
our previous study [17]: intermittent intravenous doses of 0.02
mg/kg every 4 hours for a maximum of 72 hours. This dose
was based on arbitrary extrapolations from doses used for
other indications in adults [38,39] and it was considered a 'low
dose'; nonetheless, a subset of patients developed ischemia.
Further studies are therefore needed to ascertain the ideal
dosage and schedule in children with vasodilatory septic
shock. In this sense, a clinical tool to monitor vasoconstriction
at tissue level could be very useful. Some case reports have
been published in which gastric tonometry [20,40], the ileal
pCO2 gap [41], and the sublingual microcirculatory flow [42]
have been used to monitor splanchnic and sublingual microv-
asculature after treatment with AVP or TP.
Our results indicate that TP may have a role in the therapy of
refractory hypotension. TP administration might have influ-
enced the final prognosis of our patients. Moreover, consider
that nearly all of our patients had a desperate clinical situation
and were treated with TP as a last resource. In our opinion, at
least three children were treated in a near-death situation. In
this condition, seven of 16 children survived the septic shock
episode – a figure similar to that reported by Matok and col-
leagues [4]. On the other hand, in one case the attending phy-
sicians considered that TP was a major factor of the bad
outcome, and in two patients they decided on withdrawal of
therapy due to severe ischemia, multiple organ failure, and
anticipation of non-acceptable sequelae. Only one of seven
survivors had severe ischemic sequelae, with amputation of
lower limbs below the knees and both hands; another two chil-
dren suffered the amputation of one finger.
Our study has several limitations. Compassionate use of drugs
permits the administration of nonproven therapies, outside
clinical trials, in desperate cases; due to this fact, however, the
treatment has a high risk of being a delayed, and therefore
futile, treatment. It can be argued that if there is a rational indi-
cation for the treatment in the light of available evidence, then
to have some chance of success TP therapy should be started
Figure 1
Evolution of limbs and/or cutaneous ischemia after terlipressin (TP) treatment Evolution of limbs and/or cutaneous ischemia after terlipressin (TP) treatment.Available online http://ccforum.com/content/10/1/R20
Page 7 of 8
(page number not for citation purposes)
before the clinical situation becomes so deteriorated that
treatment is worthless.
Another drawback is the small number of patients included
and the fact that they were gathered from nine different hospi-
tals. This is justified by the fact that vasodilatory septic shock
refractory to catecholamines is rare in children [2] and there-
fore multicenter studies are required. The number of cases
precludes statistical analysis to detect factors that are corre-
lated with clinical response, adverse effects, and prognosis.
Also, in order to evaluate the effects of TP administration in fur-
ther detail, certain additional hemodynamic data, such as sys-
temic vascular resistance, the cardiac index, or calorimetry
measurements, could have been very useful. These data were
unfortunately not available in most of our patients.
Conclusion
TP therapy is effective for reversing hypotension in children
with catecholamine-resistant septic shock. This treatment may
cause significant ischemic injury and it should be considered
a last-resource treatment in the critical care setting. Our
results nevertheless indicate that TP is a promising treatment,
and they give support for future controlled clinical trials to
assess the efficacy, safety, dosage, and indications of TP in
pediatric vasodilatory septic shock.
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